ArticleBlood advances2018
Infusion of donor-derived CD8
Open access · goldAbstract read
In one paragraph
Article in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 32 citations in OpenAlex.
- Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities.The Journal of clinical investigation · 2020Trial
- Virus-Specific T-Cell Therapy for the Management of Viral Infections in the Immunocompromised.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025Review
- Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation.Frontiers in immunology · 2025Review
- HLA Haplotypes and Relapse After Hematopoietic Cell Transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Review
- Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells.Frontiers in immunology · 2024Review
- The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy.Frontiers in immunology · 2024Review
- Pre-emptive and prophylactic donor lymphocyte infusion following allogeneic stem cell transplantation.International journal of hematology · 2023Review
- How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy.Blood · 2023Article
- Beyond αβ T cells: NK, iNKT, and γδT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML.Frontiers in immunology · 2023Review
- Selective depletion of naïve T cells by targeting CD45RA.Frontiers in oncology · 2022Review
- Naive T Cells in Graft Versus Host Disease and Graft Versus Leukemia: Innocent or Guilty?Frontiers in immunology · 2022Review
- Establishment of Chimerism and Organ Transplant Tolerance in Laboratory Animals: Safety and Efficacy of Adaptation to Humans.Frontiers in immunology · 2022Review
- Optimizing allogeneic grafts in hematopoietic stem cell transplantation.Stem cells translational medicine · 2021Review
- Human cytomegalovirus infection: A considerable issue following allogeneic hematopoietic stem cell transplantation.Oncology letters · 2021Review
- Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Review
- Effective Immunosurveillance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.Cancer management and research · 2021Review
- GVHD Pathogenesis, Prevention and Treatment: Lessons From Humanized Mouse Transplant Models.Frontiers in immunology · 2021Review
- Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation.Bone marrow transplantation · 2021Article
- Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.Acta pharmaceutica Sinica. B · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Lori MufflyDivision of Blood and Marrow Transplantation and.
Kevin SheehanDivision of Blood and Marrow Transplantation and.
Randall ArmstrongDivision of Blood and Marrow Transplantation and.
Kent JensenDivision of Blood and Marrow Transplantation and.
Keri TateDivision of Blood and Marrow Transplantation and.
Andrew R RezvaniDivision of Blood and Marrow Transplantation and.
David MiklosDivision of Blood and Marrow Transplantation and.
Sally AraiDivision of Blood and Marrow Transplantation and.
Judith ShizuruDivision of Blood and Marrow Transplantation and.
Laura JohnstonDivision of Blood and Marrow Transplantation and.
Everett MeyerDivision of Blood and Marrow Transplantation and.
Wen-Kai WengDivision of Blood and Marrow Transplantation and.
Ginna G LaportDivision of Blood and Marrow Transplantation and.
Robert S NegrinDivision of Blood and Marrow Transplantation and.
Sam StroberDivision of Immunology and Rheumatology, Department of Medicine, Stanford University Medical Center, Stanford, CA.
Robert LowskyDivision of Blood and Marrow Transplantation and.
Stanford University · US
Funding
TUMOR SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN BONE MARROW TRANSPLANTATIONP01CA049605 · NCI · STANFORD UNIVERSITY · PI David B. Miklos · 1989 to 2026
$73.3MTLI/ATG CONDTIONING: KIDNEY/BLOOD STEM CELL TRANSPLANTSP01HL075462 · NHLBI · STANFORD UNIVERSITY · PI ENGLEMAN, EDGAR G. · 2004 to 2020
$27.9MStanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5MT-cell monitoring and immunotherapy for treating graft-versus-host diseaseK08HL119590 · NHLBI · STANFORD UNIVERSITY · PI MEYER, EVERETT · 2014 to 2018
$767kNCI NIH HHS P01 CA049605NHLBI NIH HHS K08 HL119590NHLBI NIH HHS P01 HL075462NIDDK NIH HHS P30 DK116074
Abstract
Murine models showed that CD8
Indexed as
Immunologic MemoryLymphocyte TransfusionAnimalsBiomarkersCD8-Positive T-LymphocytesCytokinesFlow CytometryGene ExpressionGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunohistochemistryKaplan-Meier EstimateMicePhenotypeRecurrenceBiomarkersCytokines
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.